Veracyte Inc. (12V)
XSTU
Closed
Aug 25, 2026
Day's Range
35.0752 wk Range
24.40Overview - 12V - Veracyte Inc.
Key Statistics
Valuation
Enterprise Value
-322.92M
P/E (Trailing)
‪42.23‬
PEG Ratio
‪-0.01‬
Price / Book
‪2.04‬
EV / EBITDA
‪-2.86‬
Profitability
Gross Margin
‪72.21%‬
Profit Margin
‪70.10%‬
Operating Margin
‪13.18%‬
Return on Assets
‪4.71%‬
Return on Equity
‪5.06%‬
Ownership
Shares Outstanding
79.79M
Price stats
50-Day Avg
‪45.64‬
200-Day Avg
‪36.45‬
Peers - 12V - Veracyte Inc.
Peer Comparison
Compared with companies in Diagnostics & Research listed on XSTU.
- 12VXSTUVeracyte Inc.+49.99%52-week change54.75P/E (Trailing)‪70.10%‬Profit Margin
- NL0XSTUGrail, Inc.+58.79%52-week change-6.25P/E (Trailing)‪-236.94%‬Profit Margin
- 1K9XSTUCareDx Inc.+72.93%52-week change-101.50P/E (Trailing)‪67.55%‬Profit Margin
- 8YYXSTUCoro Energy plc+86.30%52-week change0.07P/E (Trailing)‪63.04%‬Profit Margin
- 0MEXSTUTwist Bioscience Corporation+80.50%52-week change-92.62P/E (Trailing)‪50.72%‬Profit Margin
- ILUXSTUIllumina, Inc.+55.45%52-week change34.79P/E (Trailing)‪66.08%‬Profit Margin
- WX8XSTUWuXi AppTec Co., Ltd.+48.50%52-week change3.30P/E (Trailing)‪47.63%‬Profit Margin
Profile Summary - 12V - Veracyte Inc.
About
Veracyte Inc. is a global diagnostics company specializing in advanced genomic tests that provide clinicians with precise insights to diagnose and treat cancer. Its portfolio features key products such as Afirma for thyroid cancer, Decipher Prostate and Decipher Bladder for prostate and bladder cancers respectively,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
